Navigation Links
Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
Date:11/1/2007

nces in 2008.

Poniard is continuing to evaluate picoplatin administered once every two weeks in the FOLPI regimen in its ongoing Phase 1 trial and has not yet reached the maximum tolerated dose for this dosing regimen.

About Picoplatin

Picoplatin has an improved safety profile compared to existing platinum- based chemotherapeutics and was designed to overcome platinum resistance. Poniard's strategy is to develop picoplatin as a platform product that can be used second-line in patients who are resistant or refractory to currently available platinums, such as small cell lung cancer (SCLC) patients, and first-line in patients, such as CRC patients, who cannot tolerate the toxicity profile of currently marketed platinums. We also plan to advance the use of picoplatin in new combination regimens in which platinums are not currently used, such as in the treatment of hormone-refractory prostate cancer (HRPC) patients, in order to improve efficacy. In addition to the Phase 2 trial in metastatic CRC, Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

The Company is also evaluating intravenous picoplatin in an ongoing Phase 2 trial in combination with docetaxel (Taxotere(R)) and prednisone in patients with metastatic HRPC. Oral picoplatin is being evaluated in a Phase 1 clinical trial in solid tumors.

Picoplatin has been tested in more than 600 patients in Phase 1 and 2 safety and efficacy studies.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead pla
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
2. Poniard Pharmaceuticals Announces Clinical Data from Picoplatin Phase 2 Small Cell Lung Cancer Trial To Be Presented at American Society of Clinical Oncology Annual Meeting
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... Auf seiner am ... veranstalteten F&E-Tagung meldete Astellas Fortschritte im ... Forschungsrahmenprogramms. Die Tagung bot Astellas die Gelegenheit, ... Programme und die Konzernstrategie des Unternehmens zu ... aktuelle Meldungen zu den Astellas-Initiativen in den ...
(Date:7/13/2014)... , July 13, 2014  Eli Lilly ... announced results from its non-clinical study in genetically ... version of the beta-amyloid antibody N3pG and beta-secretase ... therapy was more effective in removing clumps of ... that is thought to lead to Alzheimer,s disease ...
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, Inc. ... vegetable-glycol solution for use in portable vaporizers, which ... active ingredients in cannabis, cannabidiol offers consumers a ... devices, and other vaporizer technology. Photo ... naturally contains 483 different compounds which are currently ...
Breaking Medicine Technology:Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 2Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 3Astellas erörtert Pipeline-Fortschritte auf F&E-Tagung 4New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 2New Data Shows Combination Therapy is More Effective than Monotherapy in Removing Beta-Amyloid Plaques from the Brains of Mice 3VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2
... is,being released by The Philadelphia AIDS Consortium:, ... with its network of eleven (11) community-based organization,sites ... of 30 AmeriCorps ACTS members working throughout New,Jersey, ... 2008: 9 a.m. until Noon; Media Focused,Event 10:30 ...
... highlights:, In a small study, miniaturized heart pumps ... The devices are not approved for general use ... In a recent study, nine,pediatric patients with severe heart ... days with miniaturized heart assist pumps while,awaiting a heart ...
Cached Medicine Technology:Unprecedented 8th Year Start Up of National Direct AmeriCorps Program Access to Care Through Service (ACTS) Parent, Lead Organization The Philadelphia AIDS Consortium and World Health Care Infrastructures 2American Heart Association Journal Report: Miniaturized Heart Pumps May Be Effective for Children Awaiting Transplant 2
(Date:7/13/2014)... 13, 2014 Athletes with a certain ... from concussions, according to research presented today at the ... Annual Meeting. The research marks the first of its ... the known physical events that occur after a head ... long allele in the (GT)n genotype were four times ...
(Date:7/13/2014)... (PRWEB) July 13, 2014 Recently, MyDressCity.com, ... and women’s special occasion outfits, has released its new ... all the new products are available at discounted prices. ... 26, 2014. , In the company’s online shop, ... all of them are made with great materials. MyDressCity.com’s ...
(Date:7/13/2014)... A decreased ability to identify odors might ... disease, while examinations of the eye could indicate ... Alzheimer,s, in the brain, according to the results ... Alzheimer,s Association International Conference 2014 (AAIC 2014) in ... decreased ability to identify odors was significantly associated ...
(Date:7/13/2014)... July 13, 2014 Celebrity fitness trainer ... formed a promotional partnership with Aqua Health Labs for ... Omega-3 EPA supplement . The collaboration was recently announced ... fitness trainer , actor, model, and a two ... for A-List celebrities, he has prepared stars including Demi ...
(Date:7/13/2014)... Wa (PRWEB) July 13, 2014 According ... Vkool.com, this is a comprehensive program that teaches people ... peripheral neuropathy without medications. This program also ... relieving symptoms of peripheral neuropathy , including numbness, prickling, ... in its review that this home treatment program can ...
Breaking Medicine News(10 mins):Health News:Genetic Factors May Be Responsible for Slowing Concussion Recovery in Athletes 2Health News:Cheap Elegant Quinceanera Dresses Unveiled by MyDressCity.com 2Health News:Smell and eye tests show potential to detect Alzheimer's early 2Health News:Smell and eye tests show potential to detect Alzheimer's early 3Health News:Smell and eye tests show potential to detect Alzheimer's early 4Health News:Smell and eye tests show potential to detect Alzheimer's early 5Health News:Smell and eye tests show potential to detect Alzheimer's early 6Health News:Smell and eye tests show potential to detect Alzheimer's early 7Health News:Celebrity Fitness Expert Supports Revolutionary New Health Supplement 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 2Health News:The Peripheral Neuropathy Program Review Exposes Randall Labrum's Peripheral Neuropathy Treatment Program – Vkool.com 3
... 18, 2010 Research exploring the progression of colon ... polyp detection was among the clinical science presented at ... of Gastroenterology in San Antonio today. The Progression ... in the colon known as sessile serrated adenomas (SSA) ...
... Association is re-arranging the ABCs of cardiopulmonary resuscitation ... for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care, published ... Association . , Recommending that chest compressions be ... to revive victims of sudden cardiac arrest, the ...
... from the Royal Cornwall Hospital in Truro have received a ... partners in Glasgow and Norwich into a rare form of ... Chief Scientist,s Office for Scotland and will be divided between ... Harry Dalton, a Consultant Gastroenterologist at the Royal Cornwall Hospitals ...
... on glaucoma risk in people with migraine and on ... today,s Scientific Program, to be presented at the 2010 ... of Ophthalmology (MEACO) Joint Meeting. The AAO-MEACO meeting is ... Chicago. It is the largest, most comprehensive ophthalmic education ...
... Physical and mental health benefits abound for runners who keep ... medicine expert. "Running in all seasons stimulates the secretion ... physical benefits," Dr. Kevin Plancher, head of Plancher Orthopaedics and ... release from the facility. The release of endorphins ...
... AB - Researchers at the University of Calgary Faculty ... to study how white blood cells (called neutrophils) respond ... the response. When the body is invaded by ... deployment of white blood cells to the site of ...
Cached Medicine News:Health News:Colonoscopy technique increases polyp detection in far reaches of right colon 2Health News:A new order for CPR, spelled C-A-B 2Health News:A new order for CPR, spelled C-A-B 3Health News:Hepatitis E research receives funding 2Health News:Hepatitis E research receives funding 3Health News:Blood pressure, glaucoma links in migraine patients; eye care goes digital and mobile 2Health News:Blood pressure, glaucoma links in migraine patients; eye care goes digital and mobile 3Health News:Winter Runners Reap Physical, Mental Benefits: Expert 2Health News:Images shed new light on inflammation 2
Smooth pointed tips open to 3.0 mm. Cross action curved shafts. Tip to Angle Length: 12.0 mm. Round handle....
Straight, narrowed shafts with extra fine blunted tips. Smooth handle with dull finish....
Delicate cross serrated lightly curved tips with serrated handle and polished finish. Most popular size or model....
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
Medicine Products: